ROME THERAPEUTICS
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome โ vast stretches of uncharted genetic material that have long been dismissed as โjunk DNA.โ With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
ROME THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.rometx.com
Total Employee:
11+
Status:
Active
Total Funding:
127 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, and autoimmune.
Dracen Pharmaceuticals
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Genomic Prediction
Genomic Prediction provides advanced genetic testing for IVF.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Regenosine, Inc
Regenosine is developing a first-in-class disease-modifying regenerative therapy for osteoarthritis.
Royal Emerald Pharmaceuticals
Royal Emerald Pharmaceuticals produces non-addictive alternate medicines for dilemmas of PTSD and other health consequences.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
VasoRx
VasoRx is developing RNA therapies for diseases of the cardiovascular system & oncology such as atherosclerosis and pulmonary hypertension.
Zucara Therapeutics
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.
Current Advisors List
Current Employees Featured
Founder
Investors List
Section 32
Section 32 investment in Series B - ROME Therapeutics
Mass General Brigham Ventures
Mass General Brigham Ventures investment in Series B - ROME Therapeutics
Andreessen Horowitz
Andreessen Horowitz investment in Series B - ROME Therapeutics
Casdin Capital
Casdin Capital investment in Series B - ROME Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series B - ROME Therapeutics
GV
GV investment in Series B - ROME Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - ROME Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Series B - ROME Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series A - ROME Therapeutics
GV
GV investment in Series A - ROME Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-04-26 | ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy |
Official Site Inspections
http://www.rometx.com Semrush global rank: 3.29 M Semrush visits lastest month: 4.97 K
- Host name: 149.51.237.35.bc.googleusercontent.com
- IP address: 35.237.51.149
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "ROME Therapeutics" on Search Engine
ROME Therapeutics - Crunchbase Company Profile & Funding
Founders Rosana Kapeller. Operating Status Active. Last Funding Type Series B. Company Type For Profit. ROME Therapeutics is developing novel therapies for cancer and โฆSee details»
ROME Therapeutics | LinkedIn
ROME Therapeutics | 8,629 followers on LinkedIn. Harnessing the power of the repeatome to develop a new class of therapies for cancer and autoimmune diseases. | ROME โฆSee details»
Biotech Startup Rome Therapeutics Raises $77 Million in Funding
Sep 14, 2021 Rome Therapeutics Inc., a biotech company focusing on portions of DNA that have been largely overlooked by researchers, raised $77 million in a financing โฆSee details»
ROME Therapeutics Closes Oversubscribed $72 Million Series B โฆ
Sep 12, 2023 BOSTON-- ( BUSINESS WIRE )-- ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines โฆSee details»
ROME Publishes Landmark Nature Paper Revealing First High โฆ
BOSTON, December 14, 2023 -- ( BUSINESS WIRE )-- ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop โฆSee details»
ROME Therapeutics Closes Oversubscribed $72 Million Series B โฆ
BOSTON, September 12, 2023 -- ( BUSINESS WIRE )-- ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop โฆSee details»
ROME Therapeutics Expands Science Leadership in Oncology, โฆ
Jul 19, 2021 CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, โฆSee details»
ROME Publishes Landmark Nature Paper Revealing First High โฆ
BOSTON โ December 14, 2023 โ ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious โฆSee details»
GV joins $50 million round in Rome Therapeutics to
Apr 27, 2020 Rome Therapeutics, a biotechnology startup thatโs using machine learning (ML) to explore the human genome and develop new treatments for cancer and โฆSee details»
ROME Therapeutics (@rome_tx) / Twitter
Feb 4, 2022 ROME Therapeutics. @rome_tx. We are developing novel therapies for cancer and autoimmune diseases by unlocking the role of the dark genome in human โฆSee details»
ROME Therapeutics - Funding, Financials, Valuation & Investors
ROME Therapeutics has raised a total of. $199M. in funding over 3 rounds. Their latest funding was raised on Sep 12, 2023 from a Series B round. ROME Therapeutics is โฆSee details»
ROME Therapeutics Secures $77 Million in Series B Financing to โฆ
CAMBRIDGE, Mass. โ September 14, 2021 โ ROME Therapeutics, a biotechnology company harnessing the power of the repeatome for drug development, today โฆSee details»
ROME Publishes Landmark - Business Wire
Dec 14, 2023 BOSTON-- ( BUSINESS WIRE )-- ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines โฆSee details»
Rome Therapeutics | CipherBio
To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. ROME was launched in โฆSee details»
ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief โฆ
January 04, 2024 07:00 AM Eastern Standard Time. BOSTON-- ( BUSINESS WIRE )-- ROME Therapeutics, a biotechnology company harnessing the power of the dark โฆSee details»
Rome Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
May 2, 2023 About ROME ROME Therapeutics is developing novel therapies for a range of serious diseases, including autoimmune disease, cancer, and neurodegeneration, by โฆSee details»
Series B - ROME Therapeutics - 2023-09-12 - Crunchbase
Sep 12, 2023 rometx.com โ ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development โฆSee details»
Press Releases โ ROME Therapeutics
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease โฆSee details»
ROME Therapeutics - Contacts, Employees, Board Members, โฆ
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.See details»